Avectas, a cell engineering technology business and Vycellix, Inc. an immuno-discovery cell & gene therapy company, have entered into a collaboration to develop new approaches for cell-based immunotherapeutic products.   The companies will collaborate on the delivery of Vycellix’s RNA immunomodulator VY-M using Avectas’ cell engineering platform, Solupore to address current limitations for cell-based therapies, in particular the need to accelerate the manufacturing process, re...